Want to join the conversation?
Biopharmaceutical company $ABBV secured FDA approval for IMBRUVICA as a first-line treatment for patients with CLL in 1Q16. In April, the company received FDA approval for Venclexta, another therapy for the treatment for CLL. Venclexta was approved for patients with relapsed/refractory CLL.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.